Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer
Keywords: NSCLC; AUY922; HSP90 inhibitor; EGFR mutation; KRAS mutation; ALK rearrangement;